Third generation selective estrogen receptor modulators benefits beyond bone: effects on breast

被引：1

作者：

Coronado Martin, Pluvio J. ^{[1
]}

Calaf Alsina, Joaquin ^{[2
]}

机构：

[1] Univ Complutense Madrid, Dept Obstet & Ginecol, Hosp Clin San Carlos, Madrid, Spain

[2] Univ Autonoma Barcelona, Serv Obstet & Ginecol, Hosp Santa Creu & St Pau, E-08193 Barcelona, Spain

来源：

MEDICINA CLINICA | 2013年 / 140卷 / 05期

关键词：

Selective estrogen receptor modulators; Bazedoxifene; Raloxifene; Tamoxifene; Breast cancer; VERTEBRAL FRACTURE RISK; POSTMENOPAUSAL WOMEN; CANCER RISK; RANDOMIZED-TRIAL; RALOXIFENE; TAMOXIFEN; BAZEDOXIFENE; DENSITY; REDUCTION; PREVENTION;

D O I：

10.1016/j.medcli.2012.09.032

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The selective estrogen receptor modulators (SERMs) are substances with estrogenic/anti-estrogen effect that act differently depending on the tissue and composition. Since the discovery that tamoxifen and raloxifene (RLX) had a breast cancer preventive effect, the search for the perfect SERM has been the goal. Thus, ospemifen, arzoxifene, lasofoxifene and bazedoxifene (BZA) appeared as third-generation SERMs. Among all them, only BZA reached the stage of clinical use. BZA has been shown to have an anti-estrogen effect in experimental studies, but not a protective effect on clinical breast cancer in pivotal clinical trials (301 and extensions). However, in these studies comparing BZA versus RLX and placebo, RLX has not shown the expected preventive effect on breast cancer. This lack of effect can be the consequence of the size and characteristics of BZA's studies in a population with low incidence of breast cancer. (C) 2012 Elsevier Espana, S.L. All rights reserved.

引用

页码：217 / 222

页数：6

共 33 条

[1]

[Anonymous], 1983, Lancet, V1, P257

[2]

[Anonymous], PR NEWSWIRE

[3] Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women [J].

Barrett-Connor, Elizabeth ;

Mosca, Lori ;

Collins, Peter ;

Geiger, Mary Jane ;

Grady, Deborah ;

Kornitzer, Marcel ;

McNabb, Michelle A. ;

Wenger, Nanette K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (02) :125-137

[4] Mammographic breast density as an intermediate phenotype for breast cancer [J].

Boyd, NF ;

Rommens, JM ;

Vogt, K ;

Lee, V ;

Hopper, JL ;

Yaffe, MJ ;

Paterson, AD .

LANCET ONCOLOGY, 2005, 6 (10) :798-808

[5]

Boyd Norman F., 2009, V472, P343, DOI 10.1007/978-1-60327-492-0_15

[6] Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial [J].

Cauley, JA ;

Norton, L ;

Lippman, ME ;

Eckert, S ;

Krueger, KA ;

Purdie, DW ;

Farrerons, J ;

Karasik, A ;

Mellstrom, D ;

Ng, KW ;

Stepan, JJ ;

Powles, TJ ;

Morrow, M ;

Costa, A ;

Silfen, SL ;

Walls, EL ;

Schmitt, H ;

Muchmore, DB ;

Jordan, VC .

BREAST CANCER RESEARCH AND TREATMENT, 2001, 65 (02) :125-134

[7] Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: Insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens [J].

Chang, Ken C. N. ;

Wang, Yihe ;

Bodine, Peter V. N. ;

Nagpal, Sunil ;

Komm, Barry S. .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2010, 118 (1-2) :117-124

[8] American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition [J].

Chlebowski, RT ;

Col, N ;

Winer, EP ;

Collyar, DE ;

Cummings, SR ;

Vogel, VG ;

Burstein, HJ ;

Eisen, A ;

Lipkus, I ;

Pfister, DG .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) :3328-3343

[9]

Clarke M, 1998, LANCET, V351, P1451

[10]

Coronado PJ, 2006, GINECOL OBSTET CLIN, V7, P153

← 1 2 3 4 →